Table 1.
Demographic, clinical characteristics and medication class selected of total sample and by those who self-selected (n=140) and those who speak with a pharmacist (n=62).
| Survey item | All participants (n=202) | Self-Selected | p-value | |
|---|---|---|---|---|
| Yes (n=140) | No (n=62) | |||
| Gender | ||||
| Female | 137 (67.8%) | 100 (71.4%) | 37 (59.7%) | 0.105 |
| Male | 65 (32.2%) | 40 (28.6%) | 25 (40.3%) | |
| Age | ||||
| < 18 years old | 15 (7.4%) | 12 (8.57%) | 4 (4.84%) | |
| 18-39 years old | 75 (37.1%) | 52 (37.1%) | 23 (37.1%) | >0.05 |
| > 40 years old | 110 (54.5%) | 77 (55.0%) | 33 (53.2%) | |
| HCP diagnosed AR | 131 (64.9%) | 91 (65.0%) | 40 (64.5%) | 1.000 |
| AR symptoms (moderate-severe) | ||||
| Sneezing | 128 (63.4%) | 86 (61.4%) | 42 (67.7%) | 0.431 |
| Rhinorrhoea | 139 (68.8%) | 91 (65.0%) | 48 (77.4%) | 0.100 |
| Nasal Congestion | 129 (63.9%) | 84 (60.0%) | 45 (72.6%) | 0.112 |
| Itchy/Watery Eyes | 118 (58.4%) | 81 (57.9%) | 37 (59.7%) | 0.877 |
| Itchy Nose | 63 (31.2%) | 48 (34.3%) | 15 (24.2%) | 0.188 |
| Itchy Ears/Palate | 45 (22.3%) | 33 (23.6%) | 12 (19.4%) | 0.585 |
| Wheeze | 27 (13.4%) | 24 (17.1%) | 3 (4.8%) | 0.023 |
| Frequency of AR symptoms | ||||
| Intermittent | 91 (45.0%) | 62 (44.3%) | 29 (46.8%) | 0.761 |
| Persistent | 111 (55.0%) | 78 (55.7%) | 33 (53.2%) | |
| Seasonal* | 124 (61.4%) | 84 (60.0%) | 40 (64.5%) | 0.639 |
| Identified at least a trigger that affected their AR symptoms | 149 (73.8%) | 108 (77.1%) | 41 (66.1%) | 0.119 |
| AR symptoms impacted on at least one aspect of QOL** | 122 (60.4%) | 75 (53.6%) | 47 (75.8%) | 0.003 |
| Class of medications selected | ||||
| Oral Antihistamine | 115 (56.9%) | 82 (58.6%) | 33 (53.2%) | 0.539 |
| Intranasal Antihistamine | 2 (0.5%) | 2 (1.4%) | 0 (0%) | 1.000 |
| Intranasal Corticosteroids | 63 (31.2%) | 34 (24.3%) | 29 (46.8%) | 0.003 |
| Intranasal Decongestant | 23 (11.4%) | 17 (12.1%) | 6 (9.7%) | 0.811 |
| Oral Decongestant | 4 (2.0%) | 2 (1.4%) | 2 (3.2%) | 0.589 |
| Saline | 17 (8.4%) | 9 (6.4%) | 8 (12.9%) | 0.168 |
*
Seasonal – participants reported that their symptoms occurred seasonally or all year round in response to the question “Is there, if any, a particular time of the year that these symptom(s) occur?”
**
Aspect of QOL includes Impact on daily activities, performance at school or at work, or sleep disturbance.